IGSF4 methylation as an independent marker of human papillomavirus-positive oropharyngeal squamous cell carcinoma.

IMPORTANCE Human papillomavirus (HPV) is a known causative agent for oropharyngeal squamous cell carcinoma (OPSCC). Whereas it is becoming more firmly established that HPV-positive head and neck squamous cell carcinoma is associated with better survival outcomes, believed to be because of better response to chemoradiation therapy, the specific mechanisms for these improved survival outcomes remain underexplored. OBJECTIVE To examine the relationship between HPV status and promoter methylation in an OPSCC cohort. DESIGN, SETTING, AND PARTICIPANTS Real-time quantitative polymerase chain reaction was used to examine oncogenic HPV type 16 in a retrospective cohort of 121 patients with primary OPSCC. Aberrant promoter methylation of IGSF4, DAPK1, and ESR1 genes, known to be methylated in head and neck squamous cell carcinoma, including OPSCC, was examined by means of quantitative methylation-specific polymerase chain reaction. INTERVENTIONS Patients received standard therapy. MAIN OUTCOMES AND MEASURES Univariate associations between HPV and methylation were analyzed using Fisher exact tests followed by multivariable logistic regression. Cox proportional-hazards regression was used to model the risk of death given age, race, sex, HPV status, methylation, stage, smoking, and treatment. RESULTS In univariate logistic regression analyses, HPV-positive status was significantly associated with Caucasian race (P = .02), treatment (radiotherapy only, P = .01; chemoradiotherapy, P = .007), and IGSF4 methylation (P = .005). The final multivariate logistic model, after controlling for patient characteristics (sex, age, smoking, race, and treatment) with backward variable selection among genes, retained IGSF4 methylation (OR, 4.5 [95% CI, 1.6-12.8]; P = .005), Caucasian race (OR, 2.9 [95% CI, 1.0-8.3]; P = .053), treatment (radiotherapy only vs neither: OR, 11.62 [95% CI, 2.02-66.82]; P = .02; chemoradiotherapy vs neither: OR, 11.15 [95% CI, 1.92-64.65]; P = .01), male sex (OR, 4.7 [95% CI, 1.3-17.0]; P = .02), and younger age (OR, 0.9 [95% CI, 0.90-1.0]; P = .008) as independent predictors of HPV-positive status. Cox regression modeling indicated HPV-negative status, age, male sex, smoking, and radiation treatment as independent predictors of mortality. CONCLUSIONS AND RELEVANCE Methylation of IGSF4 is an independent predictor of HPV-positive status. DNA methylation in conjunction with HPV infection appears to play a role in OPSCC.

[1]  G. Gardner,et al.  Delineating an epigenetic continuum in head and neck cancer. , 2014, Cancer letters.

[2]  G. Divine,et al.  HPV and methylation indicators in paired tumor and saliva in HNSCC , 2013 .

[3]  G. Divine,et al.  Epigenetic Modulation of Signal Transduction Pathways in HPV-Associated HNSCC , 2013, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  Christopher R. Schmidt,et al.  HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. , 2013, The Journal of clinical investigation.

[5]  G. Divine,et al.  Improved Survival with HPV among African Americans with Oropharyngeal Cancer , 2013, Clinical Cancer Research.

[6]  Tim Fenton,et al.  Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma , 2013, Genome Medicine.

[7]  R. Shaw,et al.  The epigenetic landscape of oral squamous cell carcinoma , 2013, British Journal of Cancer.

[8]  G. Divine,et al.  Significance of p16 in Site-specific HPV Positive and HPV Negative Head and Neck Squamous Cell Carcinoma. , 2012, Cancer and clinical oncology.

[9]  K. Ang,et al.  Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Gardner,et al.  Human Papillomavirus Outcomes in an Access-to-Care Laryngeal Cancer Cohort , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[11]  G. Mills,et al.  Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival , 2012, Clinical Cancer Research.

[12]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Maureen A Sartor,et al.  Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis , 2011, Epigenetics.

[14]  Steven S. Chang,et al.  Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance , 2011, Clinical Cancer Research.

[15]  W. Thorstad,et al.  Human papillomavirus-related squamous cell carcinoma of the oropharynx: a comparative study in whites and African Americans. , 2011, Archives of otolaryngology--head & neck surgery.

[16]  Gypsyamber D'Souza,et al.  HPV-associated head and neck cancer: a virus-related cancer epidemic. , 2010, The Lancet. Oncology.

[17]  S. Lippman,et al.  Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) , 2010, Head & neck oncology.

[18]  M. Suntharalingam,et al.  Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients , 2009, Cancer Prevention Research.

[19]  Alyce A. Chen,et al.  Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. , 2009, Carcinogenesis.

[20]  R. Shaw,et al.  The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. , 2008, Archives of otolaryngology--head & neck surgery.

[21]  K. Gustafson,et al.  Quantitative methylation‐specific PCR for the detection of aberrant DNA methylation in liquid‐based Pap tests , 2008, Cancer.

[22]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[23]  S. Sethi,et al.  Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. , 2007, Archives of otolaryngology--head & neck surgery.

[24]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[25]  T. Kouzarides,et al.  Viral oncoproteins target the DNA methyltransferases , 2007, Oncogene.

[26]  H. Boezen,et al.  Assessment of gene promoter hypermethylation for detection of cervical neoplasia , 2006, International journal of cancer.

[27]  J. Schouten,et al.  Epigenetic events of disease progression in head and neck squamous cell carcinoma. , 2006, Archives of otolaryngology--head & neck surgery.

[28]  J. Schouten,et al.  Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. , 2006, Archives of otolaryngology--head & neck surgery.

[29]  S. Rogers,et al.  Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing , 2006, British Journal of Cancer.

[30]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[31]  M. Gillison,et al.  Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. , 2004, Seminars in oncology.

[32]  R. Weber,et al.  Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma , 2004, Clinical Cancer Research.

[33]  D. Lowy,et al.  A causal role for human papillomavirus in head and neck cancer , 2004, The Lancet.

[34]  C. Meijer,et al.  TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. , 2004, Journal of the National Cancer Institute.

[35]  J. Schouten,et al.  Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. , 2003, Archives of otolaryngology--head & neck surgery.

[36]  S. Goodman,et al.  Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[38]  H. Fukuhara,et al.  TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer , 2001, Nature Genetics.

[39]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[40]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[41]  Y. Lo,et al.  Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. , 1999, Cancer research.

[42]  P Hunt,et al.  Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Slade,et al.  National prevalence of oral HPV infection and related risk factors in the US adult population reply. , 2013, Oral diseases.

[44]  J. Stockman Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer , 2012 .

[45]  伊藤 鉄夫 Involvement of TSLC1 in progression of esophageal squamous cell carcinoma , 2005 .